Rein Therapeutics, Inc. Research And Development Expense

• Rein Therapeutics, Inc. showed a decrease of -22.6% in Research And Development Expense from 2024 to 2025.
• This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $2.49 million | Q2 2016: $2.09 million | Q3 2016: $2.61 million | Q4 2016: $3.09 million | Q1 2017: $2.94 million | Q2 2017: $3.16 million | Q3 2017: $3.83 million | Q4 2017: $4.31 million | Q1 2018: $4.85 million | Q2 2018: $5.32 million | Q3 2018: $4.32 million | Q4 2018: $3.96 million | Q1 2019: $4.17 million | Q2 2019: $4.31 million | Q3 2019: $4.48 million | Q4 2019: $4.71 million | Q1 2020: $4.07 million | Q2 2020: $2.49 million | Q3 2020: $2.68 million | Q4 2020: $1.93 million | Q1 2021: $4.32 million | Q2 2021: $3.85 million | Q3 2021: $4.28 million | Q1 2022: $5.89 million | Q2 2022: $5.43 million | Q3 2022: $4.24 million | Q1 2023: $1.81 million | Q2 2023: $187.0 thousand | Q3 2023: $22.0 thousand | Q1 2024: $3.46 million | Q2 2024: $3.74 million | Q3 2024: $3.72 million | Q1 2025: $3.05 million | Q2 2025: $4.29 million | Q3 2025: $1.68 million.
• Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Research And Development Expense has grown by 40.8%.
• Historical annual values: Fiscal year 2025: $11.03 million | Fiscal year 2024: $14.25 million | Fiscal year 2023: $3.99 million | Fiscal year 2022: $17.97 million | Fiscal year 2021: $17.01 million | Fiscal year 2020: $11.17 million | Fiscal year 2019: $17.66 million | Fiscal year 2018: $18.45 million | Fiscal year 2017: $14.24 million | Fiscal year 2016: $10.28 million | Fiscal year 2015: $7.83 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026